The Dose Podcast: Episode 3 "Shortening TB Treatment & TBTC Study 31"

23 Mar 2021
by Working Group

The Dose: Episode 3 "Shortening TB Treatment & TBTC Study 31" 

On World TB Day 2021, the Stop TB Partnership Working Group on New TB Drugs is proud to present the latest episode of The Dose podcast. The third episode will focus on the challenges of shortening DS-TB treatment and the results from the U.S. CDC TBTC Study 31 / A5449. In this episode, we address the obstacles that have previously prevented successful identification of shorter treatments for DS-TB and what the results from TBTC Study 31 could mean for future TB treatment.

Join moderator Shobha Shukla, managing editor of Citizen's News Service, as she speaks with TB treatment shortening experts Dr. Susan Dorman and Dr. Stephen Gillesie. Our moderator and speakers discuss why shorter regimens for drug-sensitive TB are needed, what the current challenges are in the field, and dive deep into the details of the exciting results from TBTC Study 31. They also address the path to adoption of a new shorter regimen and the key factors that contribute to costing analysis of novel regimens. 

Shobha Shukla, Citizen News Service, India

TB Expert
Susan Dorman, Study Director for TBTC Study 31 / A5449, USA

TB Expert
Stephen Gillespie, TB Academic Trialist, UK

More News
19 Mar 2024
For World TB Day 2024, the WGND is spotlighting a monumental achievement in TB drug research and development: the Global TB Drug Pipeline has never been bigger than it is today. The number of drug candidates being clinically evaluated for use in the treatment of adult pulmonary TB has surpassed...
3 Aug 2023
The Working Group on New TB Drugs, in collaboration with the New Diagnostics Working Group, Working Group on New Vaccines, FIND, IAVI, and TB Alliance, is co-hosting a New Tools Summit at the Marriot Champs Elysée Hotel in Paris, France on Tuesday, 14 November 2023. The WGND Annual Meeting will be...
23 Aug 2022
The PAN-TB collaboration announced initial plans for a Phase 2 clinical trial evaluating two novel drug regimens to treat Tuberculosis. Sponsored by the Bill and Melinda Gates Foundation, the PAN-TB, or “Project to Accelerate New Treatments for Tuberculosis”, collaboration brings together non-...